Astellas Pharma Inc (ALPMY)
9.46
+0.12
(+1.28%)
USD |
OTCM |
Apr 17, 15:59
Astellas Pharma Enterprise Value: 20.90B for April 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 16, 2024 | 20.90B |
April 15, 2024 | 20.78B |
April 12, 2024 | 21.28B |
April 11, 2024 | 22.60B |
April 10, 2024 | 22.50B |
April 09, 2024 | 22.92B |
April 08, 2024 | 23.01B |
April 05, 2024 | 23.16B |
April 04, 2024 | 23.12B |
April 03, 2024 | 23.32B |
April 02, 2024 | 23.50B |
April 01, 2024 | 23.46B |
March 28, 2024 | 23.43B |
March 27, 2024 | 23.77B |
March 26, 2024 | 23.98B |
March 25, 2024 | 23.70B |
March 22, 2024 | 23.91B |
March 21, 2024 | 24.00B |
March 20, 2024 | 23.79B |
March 19, 2024 | 23.66B |
March 18, 2024 | 23.61B |
March 15, 2024 | 23.56B |
March 14, 2024 | 23.28B |
March 13, 2024 | 23.32B |
March 12, 2024 | 23.44B |
Date | Value |
---|---|
March 11, 2024 | 23.68B |
March 08, 2024 | 23.19B |
March 07, 2024 | 23.43B |
March 06, 2024 | 23.53B |
March 05, 2024 | 23.52B |
March 04, 2024 | 24.02B |
March 01, 2024 | 24.14B |
February 29, 2024 | 23.75B |
February 28, 2024 | 23.84B |
February 27, 2024 | 23.86B |
February 26, 2024 | 23.93B |
February 23, 2024 | 23.86B |
February 22, 2024 | 23.80B |
February 21, 2024 | 24.09B |
February 20, 2024 | 24.13B |
February 16, 2024 | 24.05B |
February 15, 2024 | 23.96B |
February 14, 2024 | 24.01B |
February 13, 2024 | 23.68B |
February 12, 2024 | 23.55B |
February 09, 2024 | 23.50B |
February 08, 2024 | 23.39B |
February 07, 2024 | 23.73B |
February 06, 2024 | 23.68B |
February 05, 2024 | 23.87B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
20.78B
Minimum
Apr 15 2024
31.58B
Maximum
Feb 11 2020
25.79B
Average
25.66B
Median
Sep 10 2020
Enterprise Value Benchmarks
Daiichi Sankyo Co Ltd | 48.82B |
Takeda Pharmaceutical Co Ltd | 72.34B |
Nxera Pharma Co Ltd | 1.010B |
PeptiDream Inc | 1.250B |
Stemcell Holdings Inc | -- |
Enterprise Value Related Metrics
Net Income (Quarterly) | 98.29M |
Revenue (Quarterly) | 2.858B |
Total Expenses (Quarterly) | 2.730B |
EPS Diluted (Quarterly) | 0.0546 |
Gross Profit Margin (Quarterly) | 82.01% |
Profit Margin (Quarterly) | 3.44% |
Earnings Yield | -0.09% |
Operating Earnings Yield | 0.41% |
Normalized Earnings Yield | -0.3933 |